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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERColchicine and the Heart 1817
Spyridon Deftereos, Georgios Giannopoulos, Nikolaos Papoutsidakis, Vasiliki Panagopoulou,
Charalampos Kossyvakis, Konstantinos Raisakis, Michael W. Cleman, Christodoulos Stefanadis
Colchicine, a natural and ancient drug, is traditionally considered the staple therapy for gout
and a second-line treatment for pericarditis. It is commonly classiﬁed as an anti-inﬂammatory
agent although it has a unique mechanism of action; it inhibits microtubule polymerization,
thus affecting any process that requires cytoskeletal changes, including cell mitosis and
neutrophil motility. Recent studies suggest that colchicine may be useful in a wider spectrum
of cardiovascular diseases than pericarditis. In this review, Deftereos and colleagues present
the biochemical characteristics, mechanism of action, and side effects of colchicine, as well as
data suggesting its utility for preventing post-operative atrial ﬁbrillation, as a treatment for
stable coronary disease, and for preventing restenosis.CLINICAL RESEARCH CARDIOMETABOLIC RISKLow HDL-C Is Associated With Cardiac Risk in Patients on Optimal Medical Therapy 1826
Subroto Acharjee, William E. Boden, Pamela M. Hartigan, Koon K. Teo, David J. Maron,
Steven P. Sedlis, William Kostuk, John A. Spertus, Marcin Dada, Bernard R. Chaitman,
G. B. John Mancini, William S. Weintraub
In this post-hoc analysis of subjects with stable ischemic heart disease (SIHD) from the
COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug
Evaluation) trial, the association between high-density lipoprotein cholesterol (HDL-C)
levels and the rate of cardiovascular events was assessed. The rate of death/myocardial
infarction (MI) was 33% lower in the highest HDL-C quartile as compared with the lowest
quartile, with quartile of HDL-C being a signiﬁcant, independent predictor of death/MI.
Among subjects with low-density lipoprotein cholesterol (LDL-C) levels <70 mg/dl, those
in the highest quintile of HDL-C had a 65% lower risk of death or MI compared with the
lowest quintile, with the HDL-C quintile demonstrating a signiﬁcant, inverse predictive
effect. These results show that low HDL-C level remains a marker of cardiac risk, even when
LDL-C is <70 mg/dl.(continued on page A-28)
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Anton P. van de Woestijne, Yolanda van der Graaf, An-Ho Liem, Maarten J. M. Cramer,
Jan Westerink, Frank L. J. Visseren, for the SMART Study Group
van de Woestijne and colleagues evaluated the risk of low high-density lipoprotein cholesterol
(HDL-C) in patients with vascular diseases. From a prospective cohort study of 6,111
patients with manifest vascular disease, the relationship of HDL-C and vascular risk was
investigated. In patients not using lipid-lowering medication at baseline, a 0.1-mmol/l higher
level of HDL-C was associated with a 5% reduced risk for all vascular events. Similar effects
were seen in patients on usual-dose lipid-lowering medication, such as simvastatin or
low-dose atorvastatin. However, in patients using intensive lipid-lowering treatment,
HDL-C levels were not associated with recurrent vascular events irrespective of low-density
lipoprotein cholesterol levels. These results conﬁrm an association between low HDL-C and
subsequent vascular risk, but suggest that intensive statin therapy can ameliorate the risk.
Editorial Comment: Jacques Genest, p. 1842HEART FAILUREClinical Characteristics of Young Adults With HF 1845
Chih M. Wong, Nathaniel M. Hawkins, Pardeep S. Jhund, Michael R. MacDonald, Scott D. Solomon,
Christopher B. Granger, Salim Yusuf, Marc A. Pfeffer, Karl Swedberg, Mark C. Petrie,
John J. V. McMurray
Wong and colleagues used data from the CHARM (Candesartan in Heart Failure
Assessment of Reduction in Mortality and Morbidity) trials to determine the characteristics
and outcomes of young adults with heart failure (HF). Patients were categorized into 5 age
groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and 70 years. The youngest patients with HF
were more likely to be obese, to be of black ethnicity, and to have idiopathic, rather than
ischemic, dilated cardiomyopathy. They were less likely to adhere to medication, salt intake,
and other dietary measures. The youngest patients were less likely to have clinical and
radiological signs of HF during hospitalization. All-cause mortality was lowest in the
youngest age group, but these patients were more likely to be rehospitalized.
Editorial Comment: Adriaan A. Voors, Peter van der Meer, p. 1855(continued on page A-32)
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Tomoko Machino-Ohtsuka, Yoshihiro Seo, Tomoko Ishizu, Akinori Sugano, Akiko Atsumi,
Masayoshi Yamamoto, Ryo Kawamura, Takeshi Machino, Kenji Kuroki, Hiro Yamasaki,
Miyako Igarashi, Yukio Sekiguchi, Kazutaka Aonuma
Machino-Ohtsuka and colleagues investigated the efﬁcacy and safety of catheter ablation
(CA) for atrial ﬁbrillation (AF) in patients with heart failure with preserved ejection fraction
(HFPEF). CA was performed in 74 consecutive patients with compensated HFPEF
(left ventricular [LV] ejection fraction >50%). During an average 3-year follow-up,
single- and multiple-procedure drug-free success rates were 27% and 45%, respectively.
Multiple procedures and pharmaceutically assisted success rate was 73%. LV systolic
indexes (LV ejection fraction, LV strain/strain rate at systole) and diastolic indexes (E/E0,
ratio of LV strain rate at diastole with early transmitral ﬂow) improved in patients
maintaining sinus rhythm at follow-up, but not in those who continued to have AF. These
results suggest that a larger randomized trial of AF ablation or usual care in patients with AF
and HFPEF should be undertaken.CARDIAC IMAGINGSex Differences in Risk Stratiﬁcation Using PET Perfusion Imaging 1866Jenna Kay, Sharmila Dorbala, Abhinav Goyal, Reza Fazel, Marcelo F. Di Carli, Andrew J. Einstein,
Robert S. Beanlands, Michael E. Merhige, Brent A. Williams, Emir Veledar, Benjamin J. W. Chow,
James K. Min, Daniel S. Berman, Sana Shah, Naveen Bellam, Javed Butler, Leslee J. Shaw
The prognostic accuracy of stress myocardial perfusion rubidium-82 positron emission
tomography (Rb-82 PET) in women has not been established. Kay and colleagues reviewed
data from more than 6,000 men and women enrolled in the PET Prognosis Registry.
Patients were followed for the occurrence of coronary artery disease (CAD) mortality, with a
median follow-up of 2.2 years. Unadjusted CAD mortality ranged from 0.9% to 12.9% for
women (p < 0.0001) and from to 1.5% to 17.4% for men (p < 0.0001), for 0% to 15%
abnormal myocardium at stress. In multivariable models, the percent abnormal stress
myocardium was independently predictive of CAD mortality in both women and men. These
results show that stress Rb-82 PET provides signiﬁcant and clinically meaningful risk
stratiﬁcation of women and men.
Editorial Comment: Amit R. Patel, Christopher M. Kramer, p. 1877(continued on page A-36)
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Christian Ott, Felix Mahfoud, Axel Schmid, Tilmann Ditting, Paul A. Sobotka, Roland Veelken,
Aline Spies, Christian Ukena, Ulrich Laufs, Michael Uder, Michael Böhm, Roland E. Schmieder
Ott and colleagues investigated the effect of renal denervation (RDN) in patients with
treatment-resistant hypertension, deﬁned as ofﬁce blood pressure (BP) 140/90 mm Hg
with at least 3 antihypertensive drugs, including a diuretic, in adequate doses and conﬁrmed
by 24-h ambulatory blood pressure monitoring (ABPM). A total of 54 patients treated with
5.1  1.4 antihypertensive drugs on average underwent RDN. Ofﬁce BP was signiﬁcantly
reduced by 13/7 mm Hg at 6 months after RDN. Similar results were seen in the subset of
patients who underwent ABPM 6 months after treatment. These results indicate that RDN
may reduce BP substantially in patients with moderate treatment-resistant hypertension.
Editorial Comment: Krishna J. Rocha-Singh, Richard E. Katholi, p. 1887PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCHMacrophage Subpopulations Are Essential for Infarct Repair 1890
Tamar Ben-Mordechai, Radka Holbova, Natalie Landa-Rouben, Tamar Harel-Adar, Micha S. Feinberg,
Ihab Abd Elrahman, Galia Blum, Fred H. Epstein, Zmira Silman, Smadar Cohen, Jonathan Leor
Ben-Mordechai and colleagues investigated the hypothesis that the favorable effects of
mesenchymal stromal cells (MSCs) on infarct repair are mediated by macrophages. In a
mouse model, MSC therapy signiﬁcantly increased the percentage of reparative M2
macrophages in the infarcted myocardium. With and without MSC therapy, transient
macrophage depletion increased mortality 30 days after myocardial infarction. Early
macrophage depletion produced negative effects on infarct size, left ventricular (LV)
remodeling, and LV function. These results show that some of the protective effects of
MSCs on infarct repair are mediated by macrophages, and this suggests that targeting
macrophages could be a novel strategy to improve infarct healing and repair.
Editorial Comment: Filip K. Swirski, Matthias Nahrendorf, p. 1902
